
Editas Medicine Inc
NASDAQ:EDIT

Intrinsic Value
The intrinsic value of one
EDIT
stock under the Base Case scenario is
1.28
USD.
Compared to the current market price of 1.91 USD,
Editas Medicine Inc
is
Overvalued by 33%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Editas Medicine Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Editas Medicine Inc
Balance Sheet Decomposition
Editas Medicine Inc
Current Assets | 224.8m |
Cash & Short-Term Investments | 221m |
Receivables | 510k |
Other Current Assets | 3.4m |
Non-Current Assets | 38.8m |
PP&E | 34.6m |
Other Non-Current Assets | 4.2m |
Free Cash Flow Analysis
Editas Medicine Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Editas Medicine Inc
Revenue
|
35.8m
USD
|
Operating Expenses
|
-243.1m
USD
|
Operating Income
|
-207.2m
USD
|
Other Expenses
|
-44m
USD
|
Net Income
|
-251.2m
USD
|
EDIT Profitability Score
Profitability Due Diligence
Editas Medicine Inc's profitability score is 10/100. The higher the profitability score, the more profitable the company is.

Score
Editas Medicine Inc's profitability score is 10/100. The higher the profitability score, the more profitable the company is.
EDIT Solvency Score
Solvency Due Diligence
Editas Medicine Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Score
Editas Medicine Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EDIT Price Targets Summary
Editas Medicine Inc
According to Wall Street analysts, the average 1-year price target for
EDIT
is 3.44 USD
with a low forecast of 1.01 USD and a high forecast of 5.25 USD.
Dividends
Current shareholder yield for EDIT is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
EDIT
stock under the Base Case scenario is
1.28
USD.
Compared to the current market price of 1.91 USD,
Editas Medicine Inc
is
Overvalued by 33%.